 |
|
|
| |
Activity of Next Generation Integrase Inhibitor (INI) S/GSK1349572 in Subjects with HIV Exhibiting Raltegravir Resistance: Initial Results of VIKING Study (ING112961)
|
| |
| |
Reported by Jules Levin
18th Intl AIDS Conf, July 18-23 2010, Vienna, Austria
J. Eron 1, J. Durant2, I. Poizot-Martin3, J Reynes4, V Soriano5, P Kumar6, G Richmond7, D Vittecoq8, T Fujiwara9, M Ait-Khaled10, S Min11, D Thomas11, R Cuffe10, J Yeo10
1Center for AIDS Research Clinical Core, UNC School of Medicine, NC; 2Hopital l'Archet, Nice; 3Hopital Sainte Marguerite, Marseille; 4Hopital Guide Chauliac, Montpellier;
5Hospital Carlos III, Madrid; 6Georgetown Univ, Washington; 7Fort Lauderdale;
8Hopital Paul Brousse, Villejuif; 9Shionogi & Co., Ltd., Osaka, Japan;
10GlaxoSmithKline, London; 11GlaxoSmithKline, Research Triangle Park, NC
|
| |
|
|
|
|
|
